tbuckley/cabot-search huggingface dataset:
<i>In vivo</i>evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature
Authors: Hamed Akbari, Spyridon Bakas, Jared M Pisapia, MacLean P Nasrallah, Martin Rozycki, Maria Martinez-Lage, Jennifer J D Morrissette, Nadia Dahmane, Donald M O’Rourke, Christos Davatzikos
Journal: Neuro-Oncology (2018)

Epidermal growth factor receptor variant III (EGFRvIII) is a driver mutation and potential therapeutic target in glioblastoma. Non-invasive in vivo EGFRvIII determination, using clinically acquired multiparametric MRI sequences, could assist in assessing spatial heterogeneity related to EGFRvIII, currently not captured via single-specimen analyses. We hypothesize that integration of subtle, yet distinctive, quantitative imaging/radiomic patterns using machine learning may lead to non-invasively determining molecular characteristics, and particularly the EGFRvIII mutation.
β-Blockers in Myocardial Infarction
Authors: Arjun Gupta, Sandeep R. Das, Ambarish Pandey
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mechanical Considerations for Electrospun Nanofibers in Tendon and Ligament Repair
Authors: David A. Brennan, Adriano A. Conte, Gregory Kanski, Stefan Turkula, Xiao Hu, Matthew T. Kleiner, Vince Beachley
Journal: Advanced Healthcare Materials (2018)

Electrospun nanofibers possess unique qualities such as nanodiameter, high surface area to volume ratio, biomimetic architecture, and tunable chemical and electrical properties. Numerous studies have demonstrated the potential of nanofibrous architecture to direct cell morphology, migration, and more complex biological processes such as differentiation and extracellular matrix (ECM) deposition through topographical guidance cues. These advantages have created great interest in electrospun fibers for biomedical applications, including tendon and ligament repair. Electrospun nanofibers, despite their nanoscale size, generally exhibit poor mechanical properties compared to larger conventionally manufactured polymer fiber materials. This invites the question of what role electrospun polymer nanofibers can play in tendon and ligament repair applications that have both biological and mechanical requirements. At first glance, the strength and stiffness of electrospun nanofiber grafts appear to be too low to fill the rigorous loading conditions of these tissues. However, there are a number of strategies to enhance and tune the mechanical properties of electrospun nanofiber grafts. As researchers design the next-generation electrospun tendon and ligament grafts, it is critical to consider numerous physiologically relevant mechanical criteria and to evaluate graft mechanical performance in conditions and loading environments that reflect in vivo conditions and surgical fixation methods.
Dissection sous-muqueuse endoscopique (DSME): Résultats préliminaires d'un centre européen
Authors: M Giovannini, A Badaoui, E Bories, G Monges, C Pesenti, F Caillol, JR Delpero
Journal: Endoscopy (2009)

But: La DSME a été initialement décrite par les auteurs japonais dans le traitement endoscopique du cancer superficiel de l'estomac permettant une résection »en bloc « de lésions de plus de 2cm de diamètre. Peu ou pas de séries européennes ont été publiées, nous rapportons donc une des premières expériences en matière de DSME d'un centre européen.
Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
Authors: Takashi Takeshita, Yutaka Yamamoto, Mutsuko Yamamoto-Ibusuki, Mai Tomiguchi, Aiko Sueta, Keiichi Murakami, Hirotaka Iwase
Journal: Molecular Cancer (2018)

The somatic activation of PI3K/AKT pathway mutations, PIK3CA and AKT1, and ESR1 mutations in plasma cell-free DNA (cfDNA) has been studied as a non-invasive procedure to quickly assess and monitor disease progression or therapeutic effect in breast cancer (BC) patients, but the clinical significance of these mutations in late treatment lines (TLs) remains unclear. The subjects of this study were a total of 251 plasma samples from 128 estrogen receptor-positive (ER+) BC patients. Of these plasma samples, 133 were from 73 primary BC (PBC) patients, and 118 plasma samples were from 68 metastatic BC (MBC) patients. We developed droplet digital PCR (ddPCR) assays to verify the clinical significance of PIK3CA, AKT1, and ESR1 mutations in these patients. cfDNA PIK3CA mutations were observed in 15.1% of the PBC patients, while a cfDNA AKT1 mutation was observed in 1.4% of patients, and cfDNA ESR1 mutations were observed in 2.7% of patients. Patients with detectable cfDNA PIK3CA mutations were not associated with clinical outcomes. According to the TL, the prevalence of the PIK3CA and ESR1 mutations in cfDNA were lower in early TLs compared with late TLs. In the early TL group, patients with cfDNA PIK3CA mutations had a shorter time to treatment failure (TTF) than patients without mutations (P = 0.035). However, there was no statistically significant difference between patients with or without cfDNA ESR1 mutations. However, in the late TL group, patients with cfDNA ESR1 mutations had a shorter TTF than patients without mutations (P = 0.048). However, there was no statistically significant difference between patients with or without cfDNA PIK3CA mutations. Since the prevalence of cfDNA AKT1 mutation is low in both PBC and MBC patients, the impact of AKT1 mutations on the prognosis remains unclear. We have demonstrated the difference in the clinical significance of the hotspot PIK3CA, AKT1, and ESR1 mutations in cfDNA for each TL in ER+ BC patients.
ANASTOMOTIC ULCERATION AS A SOURCE OF OBSCURE GI BLEEDING IN PATIENTS AFTER SMALL BOWEL RESECTION
Authors: E Ivanova, E Tikhomirova, K Bolikhov, O Yudin, E Fedorov
Journal: Endoscopy (2018)

Anastomotic ulceration (AU) in the late period after small bowel (SB) resection as a rare source of obscure bleeding has become more evident after implementation of videocapsule endoscopy (VCE) and balloon-assisted enteroscopy (BAE), but still insufficiently studied. The aim is to evaluate the clinical features, etiology and treatment outcomes of the patients with AU of SB.
HOT AVULSION TECHNIQUE – A FIRST LINE APPROACH FOR TREATMENT OF VISIBLE RESIDUAL NEOPLASIA DURING ENDOSCOPIC MUCOSAL RESECTION OF COLORECTAL POLYPS?
Authors: I Pita, P Juliana, C Rui, D Libânio, P Pimentel-Nunes, T Pinto-Pais, M Dinis-Ribeiro, P Bastos
Journal: Endoscopy (2018)

The aim of this study was to evaluate the efficacy and safety of HA at index EMR and at EMR local recurrence.
TUNNEL-ENTRY DEHISCENCE AFTER UNEVENTFUL POEM
Authors: E Albéniz Arbizu, L Casanova Ortiz, A Elosua Gonzalez, F Estremera Arévalo, R Iglesias Picazo, I Areste Anduaga, M Gómez Alonso, J Carrascosa Gil, I Fernández-Urién, JJ Vila Costas
Journal: Endoscopy (2018)

POEM is an effective and safe treatment of esophageal motor disorders. Although the technique is relatively established and presents a moderate difficulty, some cases may be really challenging due to unusual complications.
RANDOM BIOPSIES IN PATIENTS HARBOURING CHD1 MUTATION: TIME TO CHANGE PROTOCOL?
Authors: R Castro, I Pita, D Libânio, M Dinis-Ribeiro, C Brandão
Journal: Endoscopy (2018)

Hereditary diffuse gastric cancer (HDGC) can be caused by a germline mutation in CDH1 gene. Affected individuals generally present multiple foci of signet ring cell carcinoma (SRCC) scattered throughout the gastric mucosa, which are difficult to detect by endoscopy, and prophylactic total gastrectomy remains the first therapeutic option. We aim to assess and compare the accuracy of random biopsies (according to Cambridge protocol) with targeted biopsies, in patients with pathological CHD1 germline mutation.
CLINICAL CHARACTERISTICS AND MANAGEMENT OF PATIENTS WITH GASTRIC PRECANCEROUS LESIONS (GPL) IN FRANCE: A LARGE 15-YEARS SINGLE CENTER RETROSPECTIVE STUDY
Authors: N Chapelle, M Peron, A Bourget, JF Mosnier, S Bruley des Varannes, Y Touchefeu, E Coron, E Cauchin, T Matysiak-Budnik
Journal: Endoscopy (2018)

Our aim was to analyse, in a large retrospective study, the frequency, clinical characteristics, evolution, and modalities of surveillance of GPL in France.
Abstract 2143: Clinical Impact of the Hot-Bath Test in Patients with Brugada Syndrome
Authors: Aiko Mori, Kengo Kusano, Satoshi Nagase, Kazufumi Nakamura, Hiroshi Morita, Tohru Ohe
Journal: Circulation (2008)

Background: Hot-bath related sudden death is sometimes observed and it is well known that fever aggravates ventricular arrhythmias in Brugada syndrome. Accordingly we examined the ECG changes during Hot-bath to identify high risk Brugada patients. Methods: Total 31 Brugada patients [clinically documented ventricular fibrillation (VF) in 12] were examined. Waterproof Holter-ECGs (modified-NASA: the point at a maximum ST-elevation) during Hot-bath were recorded and compared with ECGs during sodium channel blocker (pilsicainide) administration. We also compared ECG changes with the clinical characteristics (SCN5A mutation, family history of sudden death and syncopal episode). Results: Taking Hot-bath rose body temperature from 36.4±0.4°C to 38.1±1.8°C and increased ST-level significantly (0.17±0.15 to 0.31±0.25mV, P=0.0001). One patient developed VF (figure) during Hot-bath in whom ST-level was more elevated than that during pilsicainide administration. In accordance with ST-level change during Hot-bath and pilsicainide administration, we divided into two groups. Group 1 (n=11): ST-level was more elevated during Hot-bath than pilsicainide administration, and Group 2 (n=20): ST-level was less elevated during Hot-bath than pilsicainide administration. Family history of sudden death was more observed in Group1 (46%) than Group 2 (10%, P=0.02), but other parameters were not different between the groups. Conclusion: Hot-bath aggravates ST-elevation in Brugada patients. Hot-Bath test would be useful to identify high risk Brugada patients.
Comparison of Diagnostic Performance of the IgA Anti-tTG Test vs IgA Anti–Native Gliadin Antibodies Test in Detection of Celiac Disease in the General Population
Authors: Anil K. Verma, Simona Gatti, Elena Lionetti, Tiziana Galeazzi, Chiara Monachesi, Elisa Franceschini, Linda Balanzoni, Novella Scattolo, Mauro Cinquetti, Carlo Catassi
Journal: Clinical Gastroenterology and Hepatology (2018)
HELICOBACTER PYLORI RESISTANCE PATTERN OVER LAST 14 YEARS IN A UNIVERSITY TEACHING HOSPITAL
Authors: YY Hong, M Al Tarrah, K Elguzouli, S Hough, M Iqbal, B O'Connell, D O'Toole, F MacCarthy, D Kevans, S McKiernan
Journal: Endoscopy (2018)

To investigate H. Pylori resistance patterns in patients having gastroscopy with culture & sensitivity (C&S) at St. James's Hospital, over last 14 years.
Quantitative Assessment By Computerized Morphometry of Ki-67 and Intratumoral Inflammatory Infiltrate in Benign and Malignant Adrenocortical Tumors
Authors: P. Dalino Ciaramella, M. Vertemati, D. Petrella, E. Grossrubatscher, B. Zampetti, M. Boniardi, R. Pugliese, P. Loli
Journal: Endocrine Reviews (2014)
FACTORS PREDICTING INCOMPLETE SMALL BOWEL CAPSULE ENDOSCOPY
Authors: E Tsoukali, M Galanopoulos, C Chatzievangelinou, A Tsigaridas, C Pontas, G Karampekos, G Philippidis, A Christidou, N Viazis, G Mantzaris
Journal: Endoscopy (2018)

Although small bowel capsule endoscopy (SBCE) is an important diagnostic tool, rates of incomplete examinations (i.e. do not reach the caecum during the recording) have been reported up to 30%. We aimed to identify predictive factors associated with incomplete SBCE in a retrospective analysis.
Evaluation and Management of Self-injury in a Child With a Rare Genomic Variant
Authors: Rebecca A. Muhle, Hannah E. Reed, Patricia Aguayo, Jeremy Veenstra-VanderWeele
Journal: JAMA Psychiatry (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Diabetes Distress and Glycemic Control: The Buffering Effect of Autonomy Support From Important Family Members and Friends
Authors: Aaron A. Lee, John D. Piette, Michele Heisler, Ann-Marie Rosland
Journal: Diabetes Care (2018)

OBJECTIVE To examine whether autonomy support (defined as social support for an individual’s personal agency) for diabetes management from informal health supporters (family/friends) reduces the detrimental effects of diabetes distress on glycemic control. RESEARCH DESIGN AND METHODS Three hundred eight veterans with type 2 diabetes and one or more risk factors for diabetes complications completed a survey that included measures of diabetes distress and perceived autonomy support from their main informal health supporter. Hemoglobin A1c (HbA1c) data from 12 months before and after the survey were extracted from electronic medical records. Linear mixed modeling examined the main effects and interaction of autonomy support and diabetes distress on repeated measures of HbA1c over the 12 months after the survey, controlling for mean prior 12-month HbA1c, time, insulin use, age, and race/ethnicity. RESULTS Diabetes distress (B = 0.12 [SE 0.05]; P = 0.023) was associated with higher and autonomy support (B = −0.16 [SE 0.07]; P = 0.032) with lower subsequent HbA1c levels. Autonomy support moderated the relationship between diabetes distress and HbA1c (B = −0.13 [SE 0.06]; P = 0.027). Greater diabetes distress was associated with higher HbA1c at low (B = 0.21 [SE 07]; P = 0.002) but not high (B = 0.01 [SE 0.07]; P = 0.890) levels of autonomy support. CONCLUSIONS Autonomy support from main health supporters may contribute to better glycemic control by ameliorating the effects of diabetes distress. Interventions that reduce diabetes distress and enhance the autonomy supportiveness of informal supporters may be effective approaches to improving glycemic control.
Évaluation des pratiques professionnelles en endoscopie: étude multicentrique de faisabilité d'une méthode simple et reproductible d'évaluation de la qualité de la coloscopie dans des structures privées, semi privées et publiques
Authors: R Coriat, A Lecler, JL Monnin, A Soupison, O Berretta, H Roche, P Podevin, B Mesnard, C Nizou, D Sautereau, M Bouygues, C Brezault, M Gaudric, U Chaput, S Leblanc, F Prat, S Chaussade
Journal: Endoscopy (2010)

Introduction: L'EPP est une obligation légale et une nécessité dans le domaine de l'endoscopie digestive. Cette EPP doit évaluer l'ensemble des procédures rentrant en jeu avant, pendant et après l'acte. Une méthode simple et reproductible d'EPP a été développée afin d'évaluer la qualité de la coloscopie [1]. Le but de ce travail prospectif a été d'évaluer la faisabilité de cette méthode dans des centres d'endoscopie de CHU, de CHG, de PS-PH et dans des cliniques privées.
Pose de prothèse colique sans radioscopie: une série de 36 prothèses consécutives
Authors: M Antonietti, S Lecleire, E Ben Soussan, F Di Fiore, I Iwanicki-Caron, E Lerebours, P Ducrotté, B Paillot, P Michel
Journal: Endoscopy (2009)

Introduction: La pose de prothèses coliques est souvent réalisée sous radioscopie, qui n'est en fait pas toujours nécessaire. Le but de l'étude était de prouver la faisabilité, la sûreté et l'efficacité de la pose de prothèse colique sans contrôle radioscopique, par une étude rétrospective de 36 prothèses consécutives.
CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion
Authors: Chun‐Hui Jin, Yang Li, Jinxing Xia, Yuying Li, Mo Chen, Zheng Hu, Markus Y. Mapara, Wei Li, Yong‐Guang Yang
Journal: American Journal of Hematology (2018)

Persistent low levels of disease in bone marrow, an immunoprivileged tissue, are responsible for relapse following allogeneic hematopoietic cell transplantation. Using mouse models carrying primary human acute lymphoblast leukemia derived from MLL-AF9-overexpressing human hematopoietic stem cells, we demonstrate that allogeneic lymphocyte infusion (ALI)-mediated graft-vs.-leukemia effects selectively spare leukemia cells in the bone marrow. The resistance of leukemia cells to ALI within bone marrow is due to the immunosuppressive status of the tissue, as ALI achieved a significantly increased complete remission rate when leukemia cells were dislodged from bone marrow by treatment with a CXCR4 antagonist AMD3100. Adoptive transfer experiments confirmed that the frequency of leukemia-initiating cells in bone marrow was significantly decreased in the recipients treated with ALI plus AMD3100 compared to those receiving ALI only. These findings indicate that the immunoprivileged nature of bone marrow is largely responsible for relapse after immunotherapies, and that treatment with AMD3100 may offer a clinically-practical approach to improving the outcome of adoptive allogeneic cell therapy.
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
Authors: Brigette B.Y. Ma, Wan-Teck Lim, Boon-Cher Goh, Edwin P. Hui, Kwok-Wai Lo, Adam Pettinger, Nathan R. Foster, Jonathan W. Riess, Mark Agulnik, Alex Y.C. Chang, Akhil Chopra, Julie A. Kish, Christine H. Chung, Douglas R. Adkins, Kevin J. Cullen, Barbara J. Gitlitz, Dean W. Lim, Ka-Fai To, K.C. Allen Chan, Y.M. Dennis Lo, Ann D. King, Charles Erlichman, Jun Yin, Brian A. Costello, Anthony T.C. Chan
Journal: Journal of Clinical Oncology (2018)

Purpose This multinational study evaluated the antitumor activity of nivolumab in nasopharyngeal carcinoma (NPC). Tumor and plasma-based biomarkers were investigated in an exploratory analysis. Patients and Methods Patients with multiply pretreated recurrent or metastatic NPC were treated with nivolumab until disease progression. The primary end point was objective response rate (ORR) and secondary end points included survival and toxicity. The expression of programmed death-ligand 1 (PD-L1) and human leukocyte antigens A and B in archived tumors and plasma clearance of Epstein-Barr virus DNA were correlated with ORR and survival. Results A total of 44 patients were evaluated and the overall ORR was 20.5% (complete response, n = 1; partial response, n = 8). Nine patients received nivolumab for > 12 months (20%). The 1-year overall survival rate was 59% (95% CI, 44.3% to 78.5%) and 1-year progression-free survival (PFS) rate was 19.3% (95% CI, 10.1% to 37.2%). There was no statistical correlation between ORR and the biomarkers; however, a descriptive analysis showed that the proportion of patients who responded was higher among those with PD-L1 positive tumors (> 1% expression) than those with PD-L1-negative tumors. The loss of expression of one or both human leukocyte antigen class 1 proteins was associated with better PFS than when both proteins were expressed (1-year PFS, 30.9% v 5.6%; log-rank P = .01). There was no association between survival and PD-L1 expression or plasma Epstein-Barr virus DNA clearance. There was no unexpected toxicity to nivolumab. Conclusion Nivolumab has promising activity in NPC and the 1-year overall survival rate compares favorably with historic data in similar populations. Additional evaluation in a randomized setting is warranted. The biomarker results were hypothesis generating and validation in larger cohorts is needed.
5-Fluorouracil Enhances Protoporphyrin IX Accumulation and Lesion Clearance during Photodynamic Therapy of Actinic Keratoses: A Mechanism-Based Clinical Trial
Authors: Edward V. Maytin, Sanjay Anand, Margo Riha, Sara Lohser, Alejandra Tellez, Rim Ishak, Lauren Karpinski, Janine Sot, Bo Hu, Anton Denisyuk, Scott C. Davis, Angela Kyei, Allison Vidimos
Journal: Clinical Cancer Research (2018)

Abstract Purpose: Actinic keratoses (AK) are precancerous lesions that can progress to squamous cell carcinoma. Photodynamic therapy (PDT) and topical 5-fluorouracil (5FU) are commonly used agents for AK. Empirical reports suggest that combining them can improve the therapeutic response. However, the optimal combined regimen was not clear in terms of proper sequence, timing, and mechanism. This clinical study explored mechanisms of action for neoadjuvantal 5FU and PDT for treatment of AK. Patients and Methods: A bilaterally controlled trial (17 patients) was performed. One side of the body (face, scalp, forearms) received 5FU pretreatment for 6 days, whereas the other side served as no-pretreatment control. Methylaminolevulinate cream was applied to both sides for 3 hours, and protoporphyrin IX (PpIX) levels were measured by noninvasive fluorimetry and skin biopsy. After red light illumination, lesion clearance was assessed at 3, 6, 9, and 12 months after PDT. Results: PpIX levels were increased 2- to 3-fold in 5FU-pretreated lesions versus controls. Altered expression of heme-synthetic enzymes (coproporphyrinogen oxidase and ferrochelatase) and induction of p53 were observed, probably accounting for increased PpIX and subsequent cancer cell death. Relative clearance rates after PDT with or without 5FU pretreatment were 75% versus 45% at 3 months, and 67% versus 39% at 6 months, respectively; these differences were statistically significant. Conclusions: Serial 5FU and PDT improve AK clearance by at least two mechanisms, enhanced photosensitizer accumulation and p53 induction. Because 5FU and PDT are FDA-approved modalities, the combined regimen can be readily employed in clinical practice to reduce AK burden and reduce SCC risk. Clin Cancer Res; 24(13); 3026–35. ©2018 AACR.